Activation of PPARy2 by Rosiglitazone Causes Bone Loss Associated with Increased Marrow Adiposity and Decreased Osteoblast Number in Mice
Jilka RL, Lecka-Czernik B, Ali AA, O'Brien CE, Weinstein RS, Manolagas SC. Activation of PPARy2 by Rosiglitazone Causes Bone Loss Associated with Increased Marrow Adiposity and Decreased Osteoblast Number in Mice. J Bone Miner Res 16(supple 1):S319. 2001.